eton
pharmaceuticals
provides
update
fda
review
deer
park
globe
newswire
eton
pharmaceuticals
inc
nasdaq
eton
specialty
pharmaceutical
company
focused
developing
commercializing
innovative
drug
products
reported
partner
yet
received
communication
food
drug
administration
fda
regarding
decision
review
generic
drug
user
fee
act
gdufa
target
action
date
september
company
aware
information
requests
outstanding
expects
fda
communicate
decision
shortly
eton
pharmaceuticals
eton
pharmaceuticals
specialty
pharmaceutical
company
focused
developing
acquiring
commercializing
innovative
products
eton
primarily
focused
hospital
injectable
pediatric
rare
disease
products
company
first
commercial
product
biorphen
fda
approved
formulation
phenylephrine
injection
launched
december
company
lead
pediatric
product
orphan
drug
sprinkle
currently
review
fda
